Dr Kami Maddocks shares highlights from ASH 2025, including how the phase 3 EPCORE FL‑1 trial, adding a bispecific antibody to R2 in second‑line or later follicular lymphoma, showed significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results